Profluent's $2.25B Lilly Deal and Why Treating Proteins as a Language Modeling Problem Is a Bigger Story Than the Headline Suggests: Scaling Laws, Synthetic Biology, and the Compute Substrate Thesis

Thoughts on Healthcare Markets & Technology Podcast

0:00

-6:55

Paid episode

The full episode is only available to paid subscribers of Thoughts on Healthcare Markets & Technology

Profluent's $2.25B Lilly Deal and Why Treating Proteins as a Language Modeling Problem Is a Bigger Story Than the Headline Suggests: Scaling Laws, Synthetic Biology, and the Compute Substrate Thesis

Eli Lilly just paid $2.25 billion for the thesis that protein sequences are text and foundation models can design biology from scratch.

May 04, 2026

∙ Paid

The Profluent-Lilly deal, announced April 28, 2026, is structured as a multi-program collaboration focused on AI-designed enzymes for genetic medicines. This episode explains the technical thesis that justifies a check that size for a company with no clinical assets.

We examine the scaling law argument for why language modeling applied to protein sequenc…

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.